Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 77


Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study's primary analysis of 2573 patients.

Gligorov J, Ataseven B, Verrill M, De Laurentiis M, Jung KH, Azim HA, Al-Sakaff N, Lauer S, Shing M, Pivot X; SafeHer Study Group.

Eur J Cancer. 2017 Sep;82:237-246. doi: 10.1016/j.ejca.2017.05.010. Epub 2017 Jun 16.


Treatment tolerance and patient-reported outcomes favor online hemodiafiltration compared to high-flux hemodialysis in the elderly.

Morena M, Jaussent A, Chalabi L, Leray-Moragues H, Chenine L, Debure A, Thibaudin D, Azzouz L, Patrier L, Maurice F, Nicoud P, Durand C, Seigneuric B, Dupuy AM, Picot MC, Cristol JP, Canaud B; FRENCHIE Study Investigators.

Kidney Int. 2017 Jun;91(6):1495-1509. doi: 10.1016/j.kint.2017.01.013. Epub 2017 Mar 18.


Epidermal Growth Factor Receptor (EGFR) Pathway Biomarkers in the Randomized Phase III Trial of Erlotinib Versus Observation in Ovarian Cancer Patients with No Evidence of Disease Progression after First-Line Platinum-Based Chemotherapy.

Despierre E, Vergote I, Anderson R, Coens C, Katsaros D, Hirsch FR, Boeckx B, Varella-Garcia M, Ferrero A, Ray-Coquard I, Berns EM, Casado A, Lambrechts D, Jimeno A; European Organisation for Research and Treatment of Cancer-Gynaecological Cancer Group (EORTC-GCG); Groupe d’Investigateurs Nationaux pour les Etudes des Cancers de l’Ovaire (GINECO); Austrian Arbeitsgemeinschaft für Gynäkologische Onkologie (A-AGO); National Cancer Research Institute (NCRI); Australia New Zealand Gynaecological Oncology Group (ANZGOG); Mario Negri Gynecologic Oncology group (MaNGO).

Target Oncol. 2015 Dec;10(4):583-96. doi: 10.1007/s11523-015-0369-6. Erratum in: Target Oncol. 2016 Jun;11(3):429.


Systematic serological testing for hepatitis E virus in kidney transplant recipients.

Moal V, Legris T, Motte A, Vacher-Coponat H, Fages L, Jourde-Chiche N, Borentain P, Jaubert D, Gerolami R, Colson P.

J Clin Microbiol. 2015 May;53(5):1523-30. doi: 10.1128/JCM.03624-14. Epub 2015 Feb 18.


Efficacy and safety results from OCTAVIA, a single-arm phase II study evaluating front-line bevacizumab, carboplatin and weekly paclitaxel for ovarian cancer.

Gonzalez-Martin A, Gladieff L, Tholander B, Stroyakovsky D, Gore M, Scambia G, Kovalenko N, Oaknin A, Ronco JP, Freudensprung U, Pignata S; OCTAVIA Investigators.

Eur J Cancer. 2013 Dec;49(18):3831-8. doi: 10.1016/j.ejca.2013.08.002. Epub 2013 Sep 2.


6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial.

Pivot X, Romieu G, Debled M, Pierga JY, Kerbrat P, Bachelot T, Lortholary A, Espié M, Fumoleau P, Serin D, Jacquin JP, Jouannaud C, Rios M, Abadie-Lacourtoisie S, Tubiana-Mathieu N, Cany L, Catala S, Khayat D, Pauporté I, Kramar A; PHARE trial investigators.

Lancet Oncol. 2013 Jul;14(8):741-8. doi: 10.1016/S1470-2045(13)70225-0. Epub 2013 Jun 11.


Predicting the short-term risk of diabetes in HIV-positive patients: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study.

Petoumenos K, Worm SW, Fontas E, Weber R, De Wit S, Bruyand M, Reiss P, El-Sadr W, Monforte AD, Friis-Møller N, Lundgren JD, Law MG; D:A:D Study Group.

J Int AIDS Soc. 2012 Oct 10;15(2):17426. doi: 10.7448/IAS.15.2.17426.


Quality indicators for colorectal cancer surgery and care according to patient-, tumor-, and hospital-related factors.

Mathoulin-Pélissier S, Bécouarn Y, Belleannée G, Pinon E, Jaffré A, Coureau G, Auby D, Renaud-Salis JL, Rullier E; Regional Aquitaine Group for Colorectal cancer GRACCOR.

BMC Cancer. 2012 Jul 19;12:297. doi: 10.1186/1471-2407-12-297.


Carpal tunnel syndrome and musculoskeletal symptoms in postmenopausal women with early breast cancer treated with exemestane or tamoxifen after 2-3 years of tamoxifen: a retrospective analysis of the Intergroup Exemestane Study.

Mieog JS, Morden JP, Bliss JM, Coombes RC, van de Velde CJ; IES Steering Committee.

Lancet Oncol. 2012 Apr;13(4):420-32. doi: 10.1016/S1470-2045(11)70328-X. Epub 2012 Jan 20.


Hemodialysis without heparin: a randomized, controlled, crossover study of two dialysis membranes (AN69ST and polysulfone F60).

Brunet P, Frances J, Vacher-Coponat H, Jaubert D, Lebrun G, Gondouin B, Duval A, Berland Y.

Int J Artif Organs. 2011 Dec;34(12):1165-71. doi: 10.5301/ijao.5000033.


[Dietary therapy in patients with chronic kidney disease].

Lebrun G, Jaubert D, El Mekaoui F, Rodde G, Falgas C, Brunet P.

Prog Urol. 2011 Nov;21(11):793-7. doi: 10.1016/j.purol.2011.07.004. Epub 2011 Sep 15. French. No abstract available.


Adjuvant trastuzumab in HER2-positive breast cancer.

Slamon D, Eiermann W, Robert N, Pienkowski T, Martin M, Press M, Mackey J, Glaspy J, Chan A, Pawlicki M, Pinter T, Valero V, Liu MC, Sauter G, von Minckwitz G, Visco F, Bee V, Buyse M, Bendahmane B, Tabah-Fisch I, Lindsay MA, Riva A, Crown J; Breast Cancer International Research Group.

N Engl J Med. 2011 Oct 6;365(14):1273-83. doi: 10.1056/NEJMoa0910383.


A GINECO randomized phase II trial of two capecitabine and weekly paclitaxel schedules in metastatic breast cancer.

Lortholary A, Hardy-Bessard AC, Bachelot T, de Rauglaudre G, Alexandre J, Bourgeois H, Jaubert D, Paraiso D, Largillier R.

Breast Cancer Res Treat. 2012 Jan;131(1):127-35. doi: 10.1007/s10549-011-1776-8. Epub 2011 Sep 24.


Myotax: a phase II trial of docetaxel plus non-pegylated liposomal doxorubicin as first-line therapy of metastatic breast cancer previously treated with adjuvant anthracyclines.

Curtit E, Nouyrigat P, Dohollou N, Levy E, Lortholary A, Gligorov J, Facchini T, Jaubert D, Maille N, Pivot X, Grangé V, Cals L.

Eur J Cancer. 2011 Nov;47(16):2396-402. doi: 10.1016/j.ejca.2011.08.004. Epub 2011 Sep 13.


[Acute renal failure in the elderly].

Lautrette A, Heng AÉ, Jaubert D, Ait Hssain A, Deteix P, Souweine B.

Nephrol Ther. 2012 Feb;8(1):57-62. doi: 10.1016/j.nephro.2011.03.007. Epub 2011 Apr 30. French.


Breast cancer care compared with clinical Guidelines: an observational study in France.

Lebeau M, Mathoulin-Pélissier S, Bellera C, Tunon-de-Lara C, Daban A, Lipinski F, Jaubert D, Ingrand P, Migeot V; REPERES Group.

BMC Public Health. 2011 Jan 20;11:45. doi: 10.1186/1471-2458-11-45.


First-line bevacizumab plus taxane-based chemotherapy for locally recurrent or metastatic breast cancer: safety and efficacy in an open-label study in 2,251 patients.

Smith IE, Pierga JY, Biganzoli L, Cortés-Funes H, Thomssen C, Pivot X, Fabi A, Xu B, Stroyakovskiy D, Franke FA, Kaufman B, Mainwaring P, Pienkowski T, De Valk B, Kwong A, González-Trujillo JL, Koza I, Petrakova K, Pereira D, Pritchard KI; ATHENA Study Group.

Ann Oncol. 2011 Mar;22(3):595-602. doi: 10.1093/annonc/mdq430. Epub 2010 Sep 5.


Myocardial infarction is a complication of factor H-associated atypical HUS.

Sallée M, Daniel L, Piercecchi MD, Jaubert D, Fremeaux-Bacchi V, Berland Y, Burtey S.

Nephrol Dial Transplant. 2010 Jun;25(6):2028-32. doi: 10.1093/ndt/gfq160. Epub 2010 Mar 19.


High prevalence of the metabolic syndrome in HIV-infected patients: impact of different definitions of the metabolic syndrome.

Worm SW, Friis-Møller N, Bruyand M, D'Arminio Monforte A, Rickenbach M, Reiss P, El-Sadr W, Phillips A, Lundgren J, Sabin C; D:A:D study group.

AIDS. 2010 Jan 28;24(3):427-35. doi: 10.1097/QAD.0b013e328334344e.


Gemcitabine-oxaliplatin combination for ovarian cancer resistant to taxane-platinum treatment: a phase II study from the GINECO group.

Ray-Coquard I, Weber B, Cretin J, Haddad-Guichard Z, Lévy E, Hardy-Bessard AC, Gouttebel MC, Geay JF, Aleba A, Orfeuvre H, Agostini C, Provencal J, Ferrero JM, Fric D, Dohollou N, Paraiso D, Salvat J, Pujade-Lauraine E; GINECO group.

Br J Cancer. 2009 Feb 24;100(4):601-7. doi: 10.1038/sj.bjc.6604878. Epub 2009 Feb 3.

Supplemental Content

Loading ...
Support Center